We used iPSCs reprogrammed from fibroblasts of a Parkinson’s disease (PD) patient carrying the LRRK2 G2019S mutation along with an isogenic control, in which the mutation was genetically rescued to the wild-type sequence by gene editing and differentiated the iPSCs into dopaminergic neurons21. This evidence concerns the gene LRRK2 and Parkinson disease.